See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: June 20, 2006

Leukemia Asthma or Gastroesophageal Reflux Disease (GERD) Erectile Dysfunction

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:


This study will evaluate the safety and effectiveness of a higher dosage of imatinib (an FDA approved drug) in people with chronic myeloid leukemia (CML) in the chronic phase. Volunteers 18-75 who are within six months of diagnosis of CML with cytogenetic confirmation of Philadelphia chromosome may be included. Females of childbearing age must have a negative serum pregnancy test within seven days prior to study drug initiation.

The research sites are located throughout the United States.

More information

Please see


Asthma or Gastroesophageal Reflux Disease (GERD)

This study will evaluate the effects of the study drug esomeprazole among asthmatics. Participants must be between 18 and 70 with a clinical diagnosis of asthma, with a maintenance asthma treatment, and with symptoms of acid reflux for at least three months.

The research sites are located across the United States.

More information

Please see or .


Erectile Dysfunction

If you have high cholesterol and erectile dysfunction (ED) you may qualify to participate in this clinical study of an approved medication, Levitra, for investigational use. Volunteers 18-64 who are taking a cholesterol lowering medication, having difficulty getting and keeping an erection, and who have been in a stable heterosexual relationship for six months may qualify.

The research site is in Walnut Creek, Calif.

More information

Please see


Copyright 2006 Thomson CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.